REBINYN
Drug
Novo Nordisk AS
Total Payments
$2.8M
Transactions
1,710
Doctors
174
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $459,987 | 316 | 38 |
| 2020 | $545,419 | 296 | 25 |
| 2019 | $712,004 | 497 | 36 |
| 2018 | $492,534 | 331 | 84 |
| 2017 | $595,163 | 270 | 16 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.3M | 1,301 | 83.7% |
| Travel and Lodging | $239,097 | 133 | 8.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $164,538 | 41 | 5.9% |
| Consulting Fee | $40,590 | 31 | 1.4% |
| Food and Beverage | $13,207 | 199 | 0.5% |
| Education | $161.35 | 5 | 0.0% |
Payments by Type
Research
$2.3M
1,301 transactions
General
$457,593
409 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NN7999-3895 | Novo Nordisk AS | $1.8M | 0 |
| NN7999-4260 | Novo Nordisk AS | $362,590 | 0 |
| NN7999-3774 | Novo Nordisk AS | $198,954 | 0 |
| NN7999-3774, NN7999-3895 | Novo Nordisk Inc | $1,540 | 0 |
Top Doctors Receiving Payments for REBINYN — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Pediatric Hematology-Oncology | New York, NY | $5,215 | 4 |
| , M.D | Pediatrics | Nashville, TN | $3,987 | 4 |
| , MD | Pediatrics | Nashville, TN | $3,268 | 5 |
| , MD | Pediatric Hematology-Oncology | Charleston, SC | $3,230 | 3 |
| , MD | Pediatric Hematology-Oncology | Ann Arbor, MI | $2,917 | 4 |
| , M.D | Pediatrics | Phoenix, AZ | $2,430 | 2 |
| , MD | Hematology & Oncology | Louisville, KY | $2,430 | 2 |
| , MD | Pediatrics | Washington, DC | $1,700 | 1 |
| , M.D | Pediatric Hematology-Oncology | Milwaukee, WI | $1,530 | 2 |
| , M.D | Pediatrics | Oklahoma City, OK | $1,530 | 2 |
| , M.D | Pediatrics | Peoria, IL | $1,530 | 2 |
| , M.D | Pediatrics | Albuquerque, NM | $1,530 | 2 |
| , MD | Pediatrics | Dallas, TX | $1,530 | 2 |
| , MD | Pediatric Hematology-Oncology | Miami, FL | $1,530 | 2 |
| , MD | Pediatric Hematology-Oncology | Aurora, CO | $1,360 | 1 |
| , NP | Pediatrics | San Antonio, TX | $1,150 | 1 |
| , MD | Pediatric Hematology-Oncology | Detroit, MI | $116.97 | 1 |
| , M.D | Pediatric Hematology-Oncology | Madera, CA | $116.34 | 1 |
| , M.D | Pediatric Hematology-Oncology | Madera, CA | $116.34 | 1 |
| , M.D | Hematology & Oncology | Baltimore, MD | $112.94 | 1 |
| , M.D | Hematology & Oncology | Charlottesville, VA | $112.94 | 1 |
| , MD | Pediatric Hematology-Oncology | Augusta, GA | $101.16 | 4 |
| , MD | Hematology & Oncology | Memphis, TN | $93.11 | 1 |
| , M.D | Pediatric Hematology-Oncology | Greenville, SC | $88.22 | 1 |
| , M.D | Pediatrics | Charleston, SC | $87.73 | 1 |
Ad
Manufacturing Companies
- Novo Nordisk AS $2.6M
- Novo Nordisk Inc $227,689
Product Information
- Type Drug
- Total Payments $2.8M
- Total Doctors 174
- Transactions 1,710
About REBINYN
REBINYN is a drug associated with $2.8M in payments to 174 healthcare providers, recorded across 1,710 transactions in the CMS Open Payments database. The primary manufacturer is Novo Nordisk AS.
Payment data is available from 2017 to 2021. In 2021, $459,987 was paid across 316 transactions to 38 doctors.
The most common payment nature for REBINYN is "Unspecified" ($2.3M, 83.7% of total).
REBINYN is associated with 4 research studies, including "NN7999-3895" ($1.8M).